MedTrace Logo

First-Line Chemotherapy and Panitumumab in Advanced Non-Small Cell Lung Cancer

NCT01038037 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 23

Last updated 2014-12-04

No results posted yet for this study

Summary

The purpose of this study is to determine whether the addition of panitumumab to standard chemotherapy in first-line treatment of advanced Non Small Cell Lung Cancer improves the treatment outcome. Patients are selected based on triple mutational status.

Conditions

  • Non Small Cell Lung Cancer

Interventions

DRUG

Carboplatin

i.v. day 1: AUC 5 x (GFR + 25) mg q3w

DRUG

Vinorelbine

i.v. day 1: 30 mg/m2 q3w Orally day 8: 60 mg/m2 q3w

DRUG

panitumumab

i.v. day 1: 9 mg/kg q3w

Sponsors & Collaborators

  • Vejle Hospital

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2013-06-30
Completion
2013-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01038037 on ClinicalTrials.gov